SCHEMBL847026

SCHEMBL847026

[CH2]CCC(C)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9364312 1.00
SCHEMBL888366 0.80
SCHEMBL29154803 0.80
SCHEMBL7621371 0.78
SCHEMBL727473 0.76
SCHEMBL22746947 0.76
SCHEMBL2783019 0.76
SCHEMBL2736332 0.76
SCHEMBL2611056 0.76
SCHEMBL7618573 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015158-A1 METALLOENZYME INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES VIAMET PHARMACEUTICALS, INC. (US) 2011-01-20 US claimed
EP-2234608-A2 METALLOENZYME INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES Viamet Pharmaceuticals, Inc. (US) 2010-10-06 EP claimed
WO-2009105140-A2 METALLOENZYME INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES VIAMET PHARMACEUTICALS, INC. (US) 2009-08-27 WO claimed
CN-100351249-C Quinolinone derivatives as tyrosine kinase inhibitors CHIRON CORP (US) 2007-11-28 CN claimed
JP-5045787-A None JP disclosed
JP-5045790-A None JP disclosed
JP-5045795-A None JP disclosed
WO-2024145346-A1 CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS LYGG CORPORATION (US) 2024-07-04 WO disclosed
US-20240132628-A1 OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE NEUBASE THERAPEUTICS, INC. 2024-04-25 US disclosed
US-20230174985-A1 MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS NEUBASE THERAPEUTICS, INC. 2023-06-08 US disclosed
US-11603530-B2 Modified peptide nucleic acid compositions NEUBASE THERAPEUTICS, INC. (US) 2023-03-14 US disclosed
WO-2022261030-A1 OLIGONUCLEOTIDE ANALOGUE MODULATORS OF ONCOGENES NEUBASE THERAPEUTICS, INC. (US) 2022-12-15 WO disclosed
EP-0224919-B1 NEW THIAZOLE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-08-14 EP disclosed
US-4963655-A ANTITUMOR AGENTS; VIRICIDES, AIDS, HERPES; ANTICANCER AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 1990-10-16 US disclosed
EP-0325973-A2 Recording liquid for ink-jet printing BASF Aktiengesellschaft (DE) 1989-08-02 EP disclosed
US-4742057-A Antiallergic thiazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-05-03 US disclosed
EP-0224919-A2 New thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-06-10 EP disclosed
EP-0090063-B1 PROCESS FOR MAKING N-(2-AMINOETHYL)AMIDES FROM OXAZOLINES AND AMINES THE DOW CHEMICAL COMPANY (US) 1985-09-11 EP disclosed
US-4207246-A REACTING UNSATURATED DIESTER WITH ORGANOSILOXANE CONTAINING SILICONBONDED HYDROGEN, CATALYST Consortium f/ur Elektrochemische Industrie GmbH (DE) 1980-06-10 US disclosed
US-4206117-A Pyridinyl aminoalkyl ethers BASF AKTIENGESELLSCHAFT (DE) 1980-06-03 US disclosed